ACN – Clinical Practice Guidelines: Evidence based information and recommendations for the management of localised prostate cancer – 2002

Authors : Australian Cancer Network

References

Level of evidence (1 – IV) as used by US Preventive Services Task Force.

Grade

Grade of recommendation - This publication provides evidence-based information and recommendations for the management of localized prostate cancer.

Coverage

Options for the management of localized prostate cancer include radical
prostatectomy, radiotherapy and no treatment. Radiotherapy includes external beam and interstitial radiotherapy (brachytherapy) treatments.

• Radical prostatectomy - patients who are likely to benefit from radical prostatectomy are those with a relatively long life expectancy (> 10 years), those with no significant surgical risk factors, low volume low PSA and those who, after being informed of the risks and benefits, prefer surgery.
  
  
• Radiotherapy- patients who are likely to benefit from external beam radiotherapy are those with a relatively long life expectancy (> 10 years), those with low volume low PSA, those with a moderately differentiated tumour and those who, after being informed of the risks and benefits, prefer external beam radiotherapy.
  
  
• Interstitial radiotherapy (brachytherapy) – patients who are likely to benefit from interstitial radiotherapy are those with low volume low-grade disease and a long life expectancy (> 10years). However, long-term follow up is limited and this needs to be stressed when patients are being informed as to the risks and benefits of this form of treatment.
  
  
• No initial treatment – patients who are likely to benefit from no initial treatment are those with well to moderately differentiated tumours with low volume disease, low PSA, a life expectancy less than ten years and those who, when fully informed of the risks and benefits of this form of treatment, have a preference for no treatment.

Source

Please follow this link for a full version of the ACN Guidelines